NEWS
RCPath submits evidence to Government’s NHS review
The Royal College of Pathologists (RCPath) has submitted evidence to Lord Darzi’s review of the NHS outlining the challenges and opportunities facing pathology services. The new Labour Government has commissioned an immediate and independent investigation of the NHS, appointing Professor Ara Darzi, world- renowned surgeon, to lead the investigation. The investigation will report in September 2024. The College has been invited to join the Expert Reference Group and has submitted evidence detailing the issues facing pathology services to inform the findings of the review. Its submission outlines the importance and necessity of well-resourced and robust pathology services in healthcare. It highlights that pathology is involved in 70% of all healthcare decisions and over 95% of clinical pathways. Points featured in the College’s submission include: a workforce that is inadequately resourced to meet current and predicted workload; lack of data on
both workforce numbers and workload, means there is no meaningful pathology workforce planning across NHS England; and ageing laboratory IT systems with a lack of interoperability that hinder effective diagnostics. The College has also highlighted areas that are currently working well and should be further supported including the automation of blood sciences and the rollout
of Community Diagnostic Centres. Dr Bernie Croal (pictured), RCPath
President commented: “Pathology is vital for prevention, diagnosis and treatment, but services are struggling to keep up with demand with some, such as perinatal pathology, failing. Lack of pathologists and scientists with increasing vacancy rates amid rising workloads leads to future service crises, such as cancer care. Expanded scientist roles, automation, digital pathology and AI will complement but not replace pathologists. If pathology services are not optimal then healthcare is not optimal. Pathology is vital.”
MIP Discovery rebrands as Tozaro
MIP Discovery has announced the company’s rebrand to Tozaro, completing its transition to becoming a technology innovator in the cell and gene therapy (CGT) bioprocessing sector. The rebrand comes at a time of significant growth for the company, following the refocusing of its mission to improve downstream processing within the CGT sector by helping to transform the development and manufacture of viral vectors, alongside its successful £7 million Series A funding round in February. The company’s updated brand identity fully supports this shift in focus, underpinning its commitment to enable innovation within CGT bioprocessing with its smart polymer technology. Tozaro’s smart polymers (pictured)
are uniquely and rationally designed using computational chemistry to create novel affinity solutions that enable users to extend beyond the boundaries of what is currently possible with biological
IVD solutions through partnership
MASTDISCS®
AST, Resistance Marker and Identification Discs in Cartridges
• Premium quality products
• Compatible with EUCAST and CLSI standards
• Bespoke service available
• 4 weeks stability in MAST®
DISCMASTER
reagents. As part of the design process, whole viruses are assessed to identify unique surface epitopes for synthetic affinity reagents to bind. A library of over 600 monomers (the building blocks of smart polymers) are screened against the identified epitopes to choose those with optimal characteristics for new smart polymer development.
WWW.PATHOLOGYINPRACTICE.COM SEPTEMBER 2024
Mast Group at ICC 3-6 Nov 2024, Istanbul
sales@mast-group.com
9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
